On February 23, 2026, Xilio Therapeutics, Inc.'s stockholders approved a proposal for a reverse stock split of shares ranging from 1-for-2 to 1-for-30, giving the board discretion over the specifics. The approval saw 55,438,144 votes for and 1,521,271 against, making it a significant event for the company.